Aeglea BioTherapeutics, Inc. (AGLE)

The chart shows the growth of $10,000 invested in Aeglea BioTherapeutics, Inc. on Apr 8, 2016 and compares it to the S&P 500 index or another benchmark. It would be worth nearly $522 for a total return of roughly -94.78%. All prices are adjusted for splits and dividends.

The Sharpe ratio shows whether the portfolio's excess returns are due to smart investment decisions or a result of taking a higher risk. The higher a portfolio's Sharpe ratio, the better its risk-adjusted performance.

The current Aeglea BioTherapeutics, Inc. Sharpe ratio is -0.94. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.

The chart below displays rolling 12-month Sharpe Ratio.

The Drawdowns chart displays portfolio losses from any high point along the way.

The table below shows the maximum drawdowns of the Aeglea BioTherapeutics, Inc.. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Aeglea BioTherapeutics, Inc. is 95.79%, recorded on Jun 30, 2022. The portfolio has not recovered from it yet.

Current Aeglea BioTherapeutics, Inc. volatility is 68.30%. The chart below shows the rolling 10-day volatility. Volatility is a statistical measure showing how big price swings are in either direction. The higher asset volatility, the riskier it is, because the price movements are less predictable.